The MIV-701-202 study was conducted in 50 patients with moderate kneeosteoarthritis who had previously received 6 months of treatment with either MIV-711 200mg once daily
More From BioPortfolio on "Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension ..."